Physician profile
Rebecca A Brooks
NPI 1316155781
$133,371.42
in general payments reported to CMS, 2019-2025
12 companies · $36K in 2025
The $36K reported for 2025 was more than what 96% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $6,315 · 2021: $21K · 2022: $19K · 2023: $12K · 2024: $26K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Consulting Fee: $7,195 · Travel and Lodging: $6,037 · Food and Beverage: $2,030 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,990.00 |
| Consulting Fee | $7,195.00 |
| Travel and Lodging | $6,037.21 |
| Food and Beverage | $2,029.57 |
| Education | $129.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $80,261.21 | 2019-2025 | Lynparza |
| Glaxosmithkline, LLC. | $47,482.44 | 2020-2025 | Jemperli, Zejula |
| Eisai INC. | $2,740.00 | 2023 | |
| Clovis Oncology, INC. | $2,221.59 | 2019 | |
| Abbvie INC. | $332.54 | 2024-2025 | |
| Caris Mpi, INC. | $136.88 | 2025 | Mi Cancer Seek |
| Tesaro, INC. | $124.99 | 2019 | |
| Ethicon US, LLC | $30.71 | 2019 | |
| Dysis Medical, INC. | $14.93 | 2020 | |
| Medical Device Business Services, INC. | $13.14 | 2023 | |
| Puma Biotechnology, INC. | $12.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.